Billionaire Investor Adds to Danaher Stake After Cutting It Earlier This Year
Lekha Gupta 3 weeks ago
Analyst RatingsAnalyst ColorEarningsGuidanceLarge CapEquities
Dan Loeb’s Third Point increased its Danaher stake to 540,000 shares in the second quarter, up from 525,000, with a $102.8 million valuation.
Dan Loeb‘s Third Point raised its stake in Danaher Corporation (NYSE:DHR) in the second quarter to 540,000 from 525,000 in the first quarter of 2026.
The stake is valued at about $102.8 million as of June 30. In the first quarter of 2026, the investor reduced his stake in Danaher to 525,000 from 600,000 in the fourth quarter of 2025.
Recent News:
- The company appointed Julie Sawyer Montgomery president and CEO and a member of its board, effective Oct. 1, 2026. Rainer Blair will retire on the same date and remain as a senior advisor through March 31, 2027, to support the leadership transition.
- Last week, the company posted third-quarter adjusted earnings of $2.11 per share, beating the analyst consensus estimate of $1.92. Revenue rose 8.5% year over year to $6.6 billion, beating the analysts’ expectations of $6.559 billion.
- For the fourth quarter of 2026, Danaher anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0% range year-over-year.
- The company expects respiratory revenue to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%.
- Danaher raised its fiscal 2026 adjusted earnings forecast from $8.45-$8.60 per share to $8.57-$8.62 per share versus the consensus of $8.51.
- The company said improving end-market conditions and growth throughout 2026 support its outlook. Excluding respiratory revenue, core revenue growth has averaged 4% to 5% in recent quarters, a range management considers a reasonable starting point for its 2027 outlook.
- Danaher announced an AI collaboration with NVIDIA Corp focused on autonomous science. Danaher will combine its scientific instruments, laboratory software, and automation technologies with NVIDIA’s accelerated computing and AI capabilities.
- The company plans to launch its first AI-powered autonomous lab to accelerate the development of custom antibodies and other molecular tools, with large-scale operations expected to begin in early 2027.
How Danaher Stacks Up vs TMO, A, IQV, WAT, ILMN
This peer comparison is based on a curated set of stocks selected for this analysis: Thermo Fisher Scientific, Inc. (TMO), Agilent Technologies Inc. (A), IQVIA Holdings Inc. (IQV), Waters Corp (WAT), and Illumina Inc (ILMN). Over the past year, Danaher gained 5.17%, trailing the peer-group average return of 52.97% by 47.80 percentage points. Danaher also trailed all five peers: Illumina Inc (+168.53%), Waters Corp (+29.55%), IQVIA Holdings Inc. (+26.80%), Thermo Fisher Scientific, Inc. (+20.30%), and Agilent Technologies Inc. (+19.67%).

Within the group, Illumina Inc was the strongest performer at +168.53%, while Agilent Technologies Inc. was the weakest at +19.67%. The remaining peers were mixed, with Thermo Fisher Scientific, Inc. up 20.30%, IQVIA Holdings Inc. up 26.80%, and Waters Corp up 29.55%.
DHR Scorecard: Bullish Momentum, Weak Value and Growth
Below is the Benzinga Edge scorecard for Danaher, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Bullish (Score: 84.36) — The stock is showing strong relative strength, consistent with its position above key moving averages.
- Quality: Neutral (Score: 46.55) — The fundamentals screen as middle-of-the-pack, suggesting the story is more about execution and cycle timing than "can’t-miss" balance-sheet strength.
- Value: Weak (Score: 13.78) — The valuation profile looks expensive versus typical peers, which can make the stock more sensitive to any growth slowdowns.
- Growth: Weak (Score: 21.91) — Growth scoring is on the softer side, so the chart may need continued momentum to keep buyers engaged.

The Verdict: Danaher’s Benzinga Edge signal reveals a momentum-led setup with a premium valuation backdrop. For longer-term bulls, the key is whether price can keep holding above its rising moving averages; for cautious investors, the low Value and Growth scores argue for patience on pullbacks rather than chasing strength.
Top ETF Exposure: EAGL, EQTY, NPFE Hold Meaningful DHR
- Eagle Capital Select Equity ETF (NYSE:EAGL): 4.78% Weight
- Kovitz Core Equity ETF (NYSE:EQTY): 3.74% Weight
- NPF Core Equity ETF (NASDAQ:NPFE): 3.31% Weight
Significance: Because DHR carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.
DHR Stock Today: Danaher Trades Higher Monday
DHR Stock Price Activity: Danaher shares are trading higher by 0.71% at $232.14 at the time of publication on Monday, according to Benzinga Pro data.
Photo via Shutterstock
More on these stocks
FDA & biotech Benzinga
Danaher Unveils Microsoft AI Partnership to Accelerate Scientific ExperimentsDanaher partners with Microsoft to build AI scientific instruments on Azure and Foundry, cutting lab experiment times by up to 83%.

Benzinga
Danaher Enters Strategic Partnership With Microsoft To Develop Smart Scientific Instruments And Interoperable Agentic Ecosystem To Connect TechnologiesThe partnership seeks to combine Danaher's scientific, workflow and instrumentation expertise with Microsoft's AI technologies, making experimental execution more streamlined and insights more…
